Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability

References

• Antonanzas F. Challenges to achieving value in drug spending in a decentralized country: the Spanish case. Value Health 2003;6(1):S52-63
   Google Scholar
• Vogler S, Espin J, Habl C. Pharmaceutical pricing and reimbursement information (PPRI) – new PPRI analysis including Spain. Pharmaceutical Policy and Law 2009;11:213-34
   Google Scholar
• Durán A, Lara J, van Waveren M. Spain: health system review. Health Systems in Transition 2006;8(4):1-208
   Google Scholar
• Habl C, Antony K, Arts D, et al. Surveying, assessing. and analysing the pharmaceutical sector in the 25 EU Member States. Österreichisches Bundesinstitut für Gesunheitswesen, Vienna, Austria; 2006. p. 1-794
   Google Scholar
• Organisation for Economic Co-operation and Development. OECD Health Data 2013
   Google Scholar
• Gumbs P, Verschuren M, Souverein P, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 2007;64(5):680-5
   PubMed Web of Science ®Google Scholar
• European Generic Medicines Association. 2011 Market Review. 2011
   Google Scholar
• Vogler S, Schmickl B. Rational use of medicines in Europe. 2010;1-16
   Google Scholar
• Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res 2013;13(1):59-72
   PubMed Web of Science ®Google Scholar
• Antonanzas F. The impact of the economic downturn on healthcare in Spain: consequences and alternatives. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):433-9
   PubMed Web of Science ®Google Scholar
• Almarza C. [Evolution of generic medicines market]. Presentation IMS Health, Madrid, 30 May 2013
   Google Scholar
• Dylst P, Vulto A, Godman B, Simoens S. Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy 2013;11(5):437-43
   PubMedGoogle Scholar
• Gutiérrez de Mesa Vázquez E, Reinares Lara P. Strategic issues in the development of a generics market: lessons from Spain and the Netherlands. J Generic Med 2006;3(2):121-30
   Google Scholar
• Moreno-Torres I. Generic drugs in Spain: price competition vs. moral hazard. 2011. XREAP No. 2011-04. Available from: http://ssrn.com/abstract=1856976
   Google Scholar
• Moreno-Torres I, Puig-Junoy J, Raya J. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain. Eur J Health Econ 2011;12:563-73
   PubMed Web of Science ®Google Scholar
• Moreno-Torres I. What if there was a stronger pharmaceutical price competition in Spain? When regulation has a similar effect to collusion. 2011. XREAP No. 2011-02. Available from: http://ssrn.com/abstract=1856872
   Google Scholar
• Simoens S, De Coster S. Sustaining generic medicines markets in Europe. Katholieke Universiteit Leuven, Leuven, Belgium; 2006. p. 1-100
   Google Scholar
• Rodríguez de la Cuerda ÁL. The Spanish generic market: opportunities and challenges. J Generic Med 2010;7(2):139-44
   Google Scholar
• European Commission. Pharmaceutical Sector Inquiry: Final Report. European commission; 2009. p. 1-533
   Google Scholar
• Konijn P. Pharmaceutical products - comparative price levels in 33 European countries in 2005. European Statistical Data Support; Luxembourg: 2007
   Google Scholar
• Vogler S. How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Pharmacoeconomics 2012;13(3):29-41
   Google Scholar
• Reinaud F. Generic drug price trends - A comparison across France, Germany, Italy, Spain and the UK. Available from: http://healthcare.blogs.ihs.com/2012/01/06/generic-drug-price-trends-france-germany-italy-spain-uk/2012
   Google Scholar
• GaBi. Spanish government introduces harsh generic price cuts. GaBi Online 2010. Available from: http://gabionline.net/Policies-Legislation/Spanish-government-introduces-harsh-generic-price-cuts
   Google Scholar
• Antonanzas F, Gómez P. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition. Pharmacoeconomics 2010;28(11):977-80
   PubMed Web of Science ®Google Scholar
• Real Decreto-ley 4/2010, de 26 de marzo, de racionalizacion del gasto farmacéutico con cargo al Sistema Nacional de Salud. 2013. Available from: http://www.boe.es/diario_boe/txt.php?id=BOE-A-2010-5030
   Google Scholar
• Puig-Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 2004;67:149-65
   PubMed Web of Science ®Google Scholar
• Antonanzas F, Oliva J, Pinillos M, Juàrez C. Economic aspects of the new Spanish laws on pharmaceutical preparations. Eur J Health Econ 2007;8(3):297-300
   PubMed Web of Science ®Google Scholar
• Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res 2009;9(6):569-81
   PubMedGoogle Scholar
• Rada AG. Mandatory generic prescribing is expected to save Spain €2bn a year. BMJ 2011;343:d4803
   Google Scholar
• Nieves Martin. [Meeting on generic medicines]. Presentation Portal de Salud de la Junta de Castilla y Leon, Madrid, 29 May 2012
   Google Scholar
• Clerigues J. [Impact and market prospects of generic medicines under the RDL 9/2011 and RDL 16/2012]. 2012
   Google Scholar
• GaBi. New Spanish prescribing laws to promote generics. GaBi Online 2011
   Google Scholar
• Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy 2011;101:146-52
   PubMed Web of Science ®Google Scholar
• Hollis A, Grootendorst P. Tendering generic drugs. What are the risks? 2012. Available from: http://www.canadiangenerics.ca/en/advocacy/docs/10.24.12%20Tendering%20Generic%20Drugs%20-%20What%20Are%20the%20Risks_FINAL.pdf
   Google Scholar
• Moreno-Torres I, Puig-Junoy J, Borell J-R. Generic entry into the regulated Spanish pharmaceutical market. Rev Ind Organ 2009;34:373-88
   Web of Science ®Google Scholar
• AESEG. La industrya y el mercado del genérico en España [Spanish] [The industry and the generic market in Spain]. Presentation AESEG, Madrid, 16 December 2009
   Google Scholar
• Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for health care systems? Eurohealth 2008;14(2):18-22
   Google Scholar
• Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharmacoecon Outcomes Res 2011;11(6):729-37
   PubMed Web of Science ®Google Scholar
• Vigeant Gomes M. Medicines policy: surviving the crisis. Presented at: 18th EGA Annual Meeting; 13–15 June 2012; St Julian’s, Malta
   Google Scholar
• Decollogny A, Eggli Y, Halfon P, Lufkin T. Determinants of generic drug substitution in Switzerland. BMC Health Serv Res 2011;11:17
   PubMed Web of Science ®Google Scholar
• Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics 2011;29(10):875-82
   PubMed Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. Overcoming challenges in market access of generic medicines in the European Union. J Generic Med 2012;9(1):21-8
   Google Scholar
• Wolters I, van den Hoogen H, de Bakker D. [Evaluation of introduction electronic prescribing system: final report]. 2003; p. 1-70
   Google Scholar
• McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res 2010;10(1):73-85
   PubMed Web of Science ®Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12(1):125-30
   PubMed Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing? Pharm Pract (Granada) 2012;10:3-8
   PubMedGoogle Scholar
• Quintal C, Mendes P. Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy 2012;104:61-8
   PubMed Web of Science ®Google Scholar